Lupin trades flat after launch of Bromfenac Ophthalmic Solution
Lupin said that it was the exclusive first-to-file for Bromfenac Ophthalmic Solution, 0.07%, and is eligible for 180-day exclusivity.
Lupin Share Price: Lupin shares were trading flat on Wednesday (January 10, 2024) after the pharma company launched Bromfenac Ophthalmic Solution, 0.07%, with approval from the US FDA.
The stock was trading at Rs 1396.80 at 9:58 am on Wednesday.
Lupin said that it was the exclusive first-to-file for Bromfenac Ophthalmic Solution, 0.07%, and is eligible for 180-day exclusivity.
"Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa® Ophthalmic Solution, 0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery," said the company in a statement on Wednesday.
Bromfenac Ophthalmic Solution (RLD Prolensa®) had estimated annual sales of USD 182 million (Rs 1515 crore) in the U.S. (IQVIA MAT November 2023).
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
EPFO Pension Schemes: Early pension, retirement pension, nominee pension and 4 other pension schemes that every private sector employee should know
Tata Motors, Muthoot Finance and 3 more: Axis Direct recommends buying these stocks for 2 weeks; check targets, stop losses
10:09 AM IST